This drug is under development by Biogen Idec. It is an intravenously administered inhibitor of HSP90.
Definition from NCI Drug Dictionary:
A small-molecule inhibitor of heat shock protein (Hsp) 90 with potential antineoplastic activity. Hsp90 inhibitor BIIB028 blocks the binding of oncogenic client proteins to Hsp90, which may result in the proteasomal degradation of these proteins and so the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as Her2/Erbb2, Akt, Raf1, Bcr-Abl, and mutated p53, in addition to other molecules involved in cell cycle regulation and immune responses.
BIIB028 is currently in a Phase I Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study, Administration of BIIB028 to Subjects With Solid Tumors. For details link to